Cargando…

P437: EFFECTIVE IMMUNOTHERAPY OF PEDIATRIC T(8;21) ACUTE MYELOID LEUKEMIA BY REPURPOSING CD3XCD19 TARGETING BISPECIFIC ANTIBODIES

Detalles Bibliográficos
Autores principales:	Wijnen, Noa, Barneh, Farnaz, Meulendijks, Thomas, Klein, Kim, Duddebach, Ester, Cornel, Annelisa, Dautzenberg, Noël, Ashtiani, Minoo, Krippner-Heidenreich, Anja, Nierkens, Stefan, Heidenreich, Olaf, Kaspers, Gertjan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429302/ http://dx.doi.org/10.1097/01.HS9.0000968656.94193.a5

Ejemplares similares

t(8;21) Acute Myeloid Leukemia as a Paradigm for the Understanding of Leukemogenesis at the Level of Gene Regulation and Chromatin Programming
por: Kellaway, Sophie, et al.
Publicado: (2020)

Nanoparticle-mediated targeting of the fusion gene RUNX1/ETO in t(8;21)-positive acute myeloid leukaemia
por: Issa, Hasan, et al.
Publicado: (2023)

P444: SINGLE CELL RNASEQ UNCOVERING THE ROLE OF A LEUKEMIC DRIVER GENE FUSION CBFΒ::MYH11 IN THE LEUKEMIC–NICHE SIGNALING
por: Derevyanko, Polina, et al.
Publicado: (2023)

The MLL–Menin Interaction is a Therapeutic Vulnerability in NUP98-rearranged AML
por: Rasouli, Milad, et al.
Publicado: (2023)

Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer
por: Liu, Huicheng, et al.
Publicado: (2021)

Paving the Way for Immunotherapy in Pediatric Acute Myeloid Leukemia: Current Knowledge and the Way Forward
por: Koedijk, Joost B., et al.
Publicado: (2021)

A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL
por: Mehta, Naveen K, et al.
Publicado: (2022)

Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody
por: Martini, Silvia, et al.
Publicado: (2020)

IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer
por: Lutz, Martina S., et al.
Publicado: (2023)

CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL
por: Reusing, Sarah B., et al.
Publicado: (2021)

MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy
por: Cornel, Annelisa M., et al.
Publicado: (2020)

Correction to: CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL
por: Reusing, Sarah B., et al.
Publicado: (2021)

Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells
por: Wathikthinnakon, Methi, et al.
Publicado: (2022)

CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model
por: Chauchet, Xavier, et al.
Publicado: (2022)

The oncogenic fusion protein RUNX1-CBFA2T1 supports proliferation and inhibits senescence in t(8;21)-positive leukaemic cells
por: Martinez, Natalia, et al.
Publicado: (2004)

Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436
por: Uckun, Fatih M., et al.
Publicado: (2021)

Monitoring Immune Responses in Neuroblastoma Patients during Therapy
por: Szanto, Celina L., et al.
Publicado: (2020)

siRNAs targeting the ERK2 signaling pathway and AML1/MTG8 fusion gene attenuate the differentiation, proliferation and growth arrest in t(8;21) leukemia
por: Bashanfer, Salem, et al.
Publicado: (2012)

Strategies to Genetically Modulate Dendritic Cells to Potentiate Anti-Tumor Responses in Hematologic Malignancies
por: Cornel, Annelisa M., et al.
Publicado: (2018)

RUNX1-ETO and RUNX1-EVI1 Differentially Reprogram the Chromatin Landscape in t(8;21) and t(3;21) AML
por: Loke, Justin, et al.
Publicado: (2017)

The Transmembrane Domains of TNF-Related Apoptosis-Inducing Ligand (TRAIL) Receptors 1 and 2 Co-Regulate Apoptotic Signaling Capacity
por: Neumann, Simon, et al.
Publicado: (2012)

A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
por: Uckun, Fatih M., et al.
Publicado: (2021)

Identification of a Dynamic Core Transcriptional Network in t(8;21) AML that Regulates Differentiation Block and Self-Renewal
por: Ptasinska, Anetta, et al.
Publicado: (2014)

SAT437 Immunotherapy Induced Pituitary Apoplexy
por: Uddin, Ashraf, et al.
Publicado: (2023)

P815: HIGH VALENCY OF IGM-2644, A CD38XCD3 IGM BISPECIFIC T CELL ENGAGER, DISPLACES DARATUMUMAB BINDING AND INDUCES POTENT MULTIPLE MYELOMA CELL KILLING
por: Hart, Kevin C., et al.
Publicado: (2023)

Post-hoc Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMA
por: Watts, Justin, et al.
Publicado: (2022)

CCNP Voice CVoice 642-437: quick reference
por: Sauer, Toby, et al.
Publicado: (2011)

SUN-437 Central Adrenal Insufficiency Unmasked by Pregnancy
por: Araque, Katherine, et al.
Publicado: (2019)

MON-437 False Positive I-131 Uptake
por: Yadav, Pavan Rajendra, et al.
Publicado: (2020)

Antiviral Activity of CD437 Against Mumps Virus
por: Kato, Fumihiro, et al.
Publicado: (2021)

Correction to Lancet Neurol 2021; 20: 437–47
Publicado: (2021)

FACSCanto II and LSRFortessa flow cytometer instruments can be synchronized utilizing single‐fluorochrome–conjugated surface‐dyed beads for standardized immunophenotyping
por: Cornel, Annelisa M., et al.
Publicado: (2020)

Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins
por: Schneider, B, et al.
Publicado: (2010)

PB2100: MANAGEMENT OF RELAPSED / REFRACTORY (R/R) B-CELL NON HODGKIN LYMPHOMA (B-NHL) WITH ANTI-CD20XCD3 BISPECIFIC ANTIBODY GLOFITAMAB. A SINGLE CENTER EXPERIENCE.
por: Giatra, C., et al.
Publicado: (2022)

P1276: DOSE RESPONSE PROFILE OF IGM-2323, A CD20XCD3 IGM BISPECIFIC T CELL ENGAGER, IN TRANSLATIONAL MODELS SUPPORTS PHASE 2 DOSE SELECTION IN NON-HODGKIN’S LYMPHOMA
por: Leabman, M. K., et al.
Publicado: (2022)

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial
por: Thieblemont, Catherine, et al.
Publicado: (2023)

Phase II-like murine trial identifies synergy between dexamethasone and dasatinib in T-cell acute lymphoblastic leukemia
por: Shi, Yuzhe, et al.
Publicado: (2020)

Characterization of high-molecular weight by-products in the production of a trivalent bispecific 2+1 heterodimeric antibody
por: Cramer, Dario A. T., et al.
Publicado: (2023)

Repurposing cabozantinib with therapeutic potential in KIT-driven t(8;21) acute myeloid leukaemias
por: Su, Kuan-Wei, et al.
Publicado: (2021)

Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding
por: Ptasinska, A, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_uvcjq9alrsh3mftv8fkalljrb5